| Literature DB >> 28824296 |
Wen-Ching Huang1, Yung-Cheng Chang2, Yi-Ming Chen3, Yi-Ju Hsu3, Chi-Chang Huang3, Nai-Wen Kan4, Sheng-Shih Chen5.
Abstract
Whey protein has been widely applied to athletes and the fitness field for muscle growth and performance improvement. Limited studies focused on the beneficial effects of whey on aerobic exercise according to biochemical assessments. In the current study, 12 elite male track runners were randomly assigned to whey and maltodextrin groups for 5 weeks' supplementation. The aim of this study was to investigate the effect of whey protein on physiological adaptions and exercise performance. During this period, three time points (pre-, post-, and end-test) were used to evaluate related biochemical parameters, body composition, and performance. The post-test was set 1 day after a marathon for injury status evaluation and the end-test was also assessed after 1-week recovery from endurance test. The results showed that the whey group exhibited significantly lower aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and creatine kinase indicators after the marathon (post-test), as well as at the end-test (p<0.016). The endurance performance in twelve-minute walk/run was also significantly elevated (p<0.012) possibly due to an increase in the muscle mass and amelioration of exercise injuries. In the current study, we demonstrated that whey protein can also be used for aerobic exercise for better physiological adaptation, in addition to resistance training. Whey protein could be also a potential nutrient supplement with a variety of benefits for amateur runners.Entities:
Keywords: aerobic exercise; clinical biochemistry; performance.; running; whey protein
Mesh:
Substances:
Year: 2017 PMID: 28824296 PMCID: PMC5562115 DOI: 10.7150/ijms.19584
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1Experimental design. Whey protein or a placebo (maltodextrin) was administrated with an isocaloric content after daily training. The 5-week experimental duration contained three time point assessments for biochemistry, body composition, and exercise performance.
Effect of supplementation on biochemical serum profile levels at three time point assessments
| Parameters | Treatments | Pre-test | Post-test | End-test | |||
|---|---|---|---|---|---|---|---|
| Main effect | Main effect | Interaction | |||||
| AST (U/L) | Placebo | 24.3±2.6a | 43.7±11.8b | 23.7±1.2a | |||
| Whey | 24±2.1ab | 26±2.0*,a | 19±2.3*,b | ||||
| ALT (U/L) | Placebo | 21.5±2.7 | 24.7±6.9 | 22.0±1.7 | 0.121 | ||
| Whey | 18.5±3.8 | 17.5±1.5* | 18.3±3.6 | ||||
| ALP (U/L) | Placebo | 62.5±8.8 | 60.5±10.2 | 69.3±8.6 | 0.703 | 0.213 | 0.817 |
| Whey | 63.7±6.3 | 59.7±11.3 | 67.3±9.3 | ||||
| LDH (U/L) | Placebo | 163.8±15a | 176.8±18b | 173±10ab | |||
| Whey | 159.2±5 | 159.2±8* | 153±9* | ||||
| CK (U/L) | Placebo | 141.8±42a | 545.3±122b | 253.2±39c | |||
| Whey | 154.8±30ab | 232.5±55*,b | 129.3±18*,a | ||||
| ALB (g/dL) | Placebo | 4.7±0.1 | 4.7±0.2 | 4.5±0.1 | 1.000 | 0.750 | |
| Whey | 4.7±0.1 | 4.7±0.1 | 4.5±0.2 | ||||
| TP (g/dL) | Placebo | 6.8±0.3 | 7.1±0.2 | 6.9±0.2 | 0.692 | 0.771 | |
| Whey | 6.9±0.3 | 7.1±0.3 | 6.9±0.1 | ||||
| BUN (mg/dL) | Placebo | 12.9±0.6a | 16.9±2.5b | 16.4±2.0b | 0.590 | ||
| Whey | 13.9±1.6 | 12.6±1.4* | 11.6±0.9* | ||||
| Creatine (mg/dL) | Placebo | 0.9±0.1 | 0.8±0.1 | 0.8±0.1 | 0.097 | 0.428 | 0.553 |
| Whey | 0.8±0.1 | 0.8±0.1 | 0.8±0.1 | ||||
| UA (mg/dL) | Placebo | 5.1±0.5 | 5.8±0.6 | 5.1±0.3 | 0.214 | 0.778 | |
| Whey | 5.4±0.6 | 5.9±0.5 | 5.4±0.2 | ||||
| GLU (mg/dL) | Placebo | 91.2±3 | 88.8±3 | 91.3±3 | 0.243 | 0.100 | |
| Whey | 91.2±1 | 89.5±3 | 92.0±3 | ||||
| TG (mg/dL) | Placebo | 73±9a | 65.2±15b | 142±43c | 0.158 | ||
| Whey | 74±7a | 45.3±9*,b | 104±34b | ||||
| TC (mg/dL) | Placebo | 177±13a | 196±13b | 165±32ab | 0.388 | ||
| Whey | 173±9 | 171±9* | 143±22 | ||||
| HDL (mg/dL) | Placebo | 68±4 | 75±2 | 61±4 | 0.945 | 0.303 | |
| Whey | 63±7 | 75±9 | 65±9 | ||||
| LDL (mg/dL) | Placebo | 88±7 | 98±18 | 102±9 | 0.489 | ||
| Whey | 86±5 | 82±4* | 76±9* | ||||
The post-test was assessed 1 day after the marathon. The main effect of supplementation (Sup.) means the whey and placebo treatment and the other main effect of time was the three time point assessments (pre-test, post-test, and end-test). Data are presented as the mean±SD for n=6 in each group. Statistical analysis was performed by a two-way ANOVA, and p values of <0.05 are considered to significantly differ. The post-hoc test was performed by a repeated Student's t-test between groups at the same time point, and significance (*) was set at an alpha level of 0.016 (0.05/3). Data in the same row (within group) followed by different letters (a, b, and c) significantly differ at p<0.016 (0.05/3). AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; CK, creatine kinase; ALB, albumin; TP, total protein; BUN, blood urea nitrogen; UA, uric acid; GLU, glucose; TG, triacylglycerol; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
General characteristics of the body composition
| Characteristic | Treatment | Pre-test | Post-test | End-test | |||
|---|---|---|---|---|---|---|---|
| Main effect | Main effect | Interaction | |||||
| Weight (kg) | Placebo | 61.6±4 | 63.8±3 | 60.3±5* | 0.196 | 0.505 | |
| Whey | 63.2±3 | 64.2±3 | 67.4±3* | ||||
| BMI (kg/m2) | Placebo | 20.4±0.9 | 20.6±0.6 | 20.0±1.2* | 0.160 | 0.643 | |
| Whey | 20.6±0.7 | 20.9±0.9 | 21.6±0.8* | ||||
| Body Fat (%) | Placebo | 11.8±2.3 | 11.9±1.2 | 11.5±0.4 | 0.225 | 0.581 | 0.502 |
| Whey | 11.5±2.5 | 10.5±2.9 | 09.9±1.8 | ||||
| SMM (kg) | Placebo | 31.0±2.3 | 30.1±2.5* | 30.3±3* | 0.473 | ||
| Whey | 32.1±1.6a | 34.3±2.4*,b | 34.7±1*,b | ||||
The post-test was assessed 1 day after the marathon. The main effect of supplementation (Sup.) means the whey and placebo treatments, and the other main effect of time was the three-time point assessments (pre-test, post-test, and end-test). Data are presented as the mean±SD for n=6 in each group. The statistical analysis was a two-way ANOVA, and p values of <0.05 were considered to significantly differ. The post hoc test was performed by a repeated Student's t-test between groups at the same time point, and significance (*) was set at an alpha level of 0.016 (0.05/3). Data in the same row (within group) followed by different letters (a, b, and c) significantly differ at p<0.016 (0.05/3).
Distance measurements obtained at 3-min intervals during the 12-min walk/run test
| Treatments | 3 min | 6 min | 9 min | 12 min | Main effect2 | Main effect | Interaction |
|---|---|---|---|---|---|---|---|
| Placebo | 946±10 | 1873±36 | 2810±85 | 3730±62 | 0.846 | 0.985 | |
| Whey | 943±17 | 1879±32 | 2800±64 | 3742±68 | |||
| Placebo | 935±28 | 1878±69 | 2725±760 | 3566±112 | |||
| Whey | 953±50 | 1889±10 | 2821±29* | 3776±58* | |||
1The post-test was assessed after 4 weeks of supplementation.
2The main effect of supplementation (Sup.) means the whey and placebo treatments, and the other main effect of time was distance records at the four time points (3, 6, 9, and 12 min). Data are presented as the mean±SD for n=6 in each group. Statistical analysis was a two-way ANOVA, and p values of <0.05 were considered to significantly differ. The post-hoc test was performed by a repeated Student's t-test between groups at the same time point, and significance (*) was set at an alpha level of 0.012 (0.05/4).